Research
Hormonal
NAFLD is associated with an increased risk of cardiac arrhythmias, specifically atrial fibrillation and ventricular arrhythmias, independent of traditional cardiovascular risk factors.
If you have NAFLD, be aware of symptoms like palpitations or irregular heartbeat. Screening for arrhythmias like atrial fibrillation is recommended, especially if you also have diabetes, as the risk is significantly elevated.
GoodSupportsHIGH confidence
Growing evidence also suggests, that NAFLD is associated with an increased risk of cardiac arrhythmias such as atrial fibrillation and ventricular arrhythmias... NAFLD was a predictor for the occurrence of atrial fibrillation, even independent of the presence of T2DM.
Why this rating
Supported by prospective cohort studies, though some heterogeneity exists in definitions.
Source
NAFLD and cardiovascular diseases: a clinical review
Philipp Kasper et al. · Clinical Research in Cardiology · 2020
DOI 10.1007/s00392-020-01709-7
narrative_reviewCited 628×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- The pathophysiological link between NAFLD and CVD is driven by systemic inflammation, endothelial dysfunction, and atherogenic dyslipidemia (specifically high ApoC3 and small dense LDL) resulting from hepatic fat accumulation and insulin resistance.Strong
- Non-alcoholic fatty liver disease (NAFLD) is independently associated with a significantly increased risk of cardiovascular disease (CVD) morbidity and mortality, particularly in patients with advanced fibrosis or non-alcoholic steatohepatitis (NASH).Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →